10x Genomics Inc (TXG) concluded trading on Thursday at a closing price of $7.70, with 3.91 million shares of worth about $30.13 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.71% during that period and on April 10, 2025 the price saw a loss of about -11.19%. Currently the company’s common shares owned by public are about 108.24M shares, out of which, 100.79M shares are available for trading.
Stock saw a price change of -3.39% in past 5 days and over the past one month there was a price change of -29.03%. Year-to-date (YTD), TXG shares are showing a performance of -46.38% which decreased to -79.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.78 but also hit the highest price of $36.46 during that period. The average intraday trading volume for 10x Genomics Inc shares is 3.03 million. The stock is currently trading -15.99% below its 20-day simple moving average (SMA20), while that difference is down -29.32% for SMA50 and it goes to -52.35% lower than SMA200.
10x Genomics Inc (NASDAQ: TXG) currently have 108.24M outstanding shares and institutions hold larger chunk of about 83.15% of that.
The stock has a current market capitalization of $941.73M and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$1.52 in the same period. It has Quick Ratio of 4.26 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TXG, volatility over the week remained 15.96% while standing at 8.20% over the month.
Stock’s fiscal year EPS is expected to drop by -0.01% while it is estimated to increase by 22.06% in next year. EPS is likely to grow at an annualized rate of 15.93% for next 5-years, compared to annual growth of -36.10% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 13, 2025 offering a Market perform rating for the stock and assigned a target price range of between $25 and $12 to it. Coverage by Leerink Partners stated 10x Genomics Inc (TXG) stock as an Outperform in their note to investors on September 03, 2024, suggesting a price target of $35 for the stock. On July 22, 2024, Jefferies Upgrade their recommendations, while on July 18, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $20. Stock get a Hold rating from Deutsche Bank on July 10, 2024.
